Following the completion of a strategic review of Cynata’s clinical development portfolio, CEO Dr Kilian Kelly sat down with Proactive Investors to discuss the review and his direction for the Company. Watch the interview here.
Or read more about it on the Cairns Post here.
Having recently completed a strategic review of its clinical development portfolio under the new leadership of Dr Kilian Kelly, CEO & Managing Director, he outlines to Ausbiz what investors can expect from the Cynata in the near and long-term. Watch the interview here (start at 18.37)
Following the change in leadership from Dr Ross Macdonald to Dr Kilian Kelly, Stockhead’s Tim Boreham examined Cynata in detail (though a mere days before the strategic review)
Dr Ross Macdonald announces his retirement, with Cynata appointing Chief Commercial Officer Dr Killian Kelly to the role of CEO and Managing Director, effective 1 July 2023. In addition, Dr David Atkins will join Cynata’s board, with Dr Stewart Washer stepping down from his position as a non-executive director.
Learn more on The Market Herald here.
Stuart explores the company's powerful stem cells platform, the great data in Graft-versus-Host Disease and the emerging opportunity in diabetic foot ulcers. We also spoke about why 2022 was such a bad year for Life Science sector investors, but why 2023 can be better.